Latest news with #Valsecchi
See - Sada Elbalad
2 days ago
- Entertainment
- See - Sada Elbalad
Luciano Pavarotti Biopic Planned
Yara Sameh Prominent Italian producer Pietro Valsecchi ('Quo Vado') is developing a high-end Luciano Pavarotti biopic. Valsecchi has secured a consulting agreement with Nicoletta Mantovani, the second wife of the late great tenor who broadened the audience for opera and became a global pop culture icon. A screenplay for the project is being penned by ace Italian screenwriter Leonardo Fasoli, a head writer on the series 'Gomorrah' which is Italy's top TV export. Mantovani, who established the Luciano Pavarotti Foundation after the maestro's death at 71, in 2007, is providing the project with documents, rare images, private letters, mementos, and more from the archives of the foundation and museum in the Northern Italian city of Modena that was Pavarotti's home. As part of the agreement, Mantovani 'will be actively involved in every aspect of the project, contributing first-hand to the narrative and artistic construction of the film,' according to a statement. Born in 1935 in Modena into a working-class family – his father was a baker, while his mother worked in a cigar factory – Luciano Pavarotti developed a passion for opera as a child thanks to his father, an amateur tenor. Thanks to his vibrant signature high C's and a knack for showmanship he became the most beloved and celebrated tenor since Enrico Caruso and one of the few opera singers to attain crossover fame. 'Luciano had a big dream, which was to bring opera back to the people, because when he was a kid opera was sung in the streets and was just like pop music today,' Mantovani told Variety. Pavarotti pursued this dream through the Three Tenors projects, a collective enterprise that saw him share the stage with Plácido Domingo and José Carreras and his 'Pavarotti and Friends' charity concerts, performing with rock stars such as Elton John, Sting, and Bono. Valsecchi, who shepherded Italy's biggest all-time box office hit, the 2016 comedy 'Quo Vado,' said he is seeking an Italian actor to play the lead and will soon be announcing a director for the project that will differentiate itself from Ron Howard-directed 2019 doc 'Pavarotti' by having a 'more Italian soul' while being 'clearly universal.' The plan is to shoot the Italian and English language Pavarotti biopic in several countries. Valsecchi is currently shopping the project to streamers and international buyers. read more New Tourism Route To Launch in Old Cairo Ahmed El Sakka-Led Play 'Sayidati Al Jamila' to Be Staged in KSA on Dec. 6 Mandy Moore Joins Season 2 of "Dr. Death" Anthology Series Don't Miss These Movies at 44th Cairo Int'l Film Festival Today Amr Diab to Headline KSA's MDLBEAST Soundstorm 2022 Festival Arts & Culture Mai Omar Stuns in Latest Instagram Photos Arts & Culture "The Flash" to End with Season 9 Arts & Culture Ministry of Culture Organizes four day Children's Film Festival Arts & Culture Canadian PM wishes Muslims Eid-al-Adha News China Launches Largest Ever Aircraft Carrier Sports Former Al Zamalek Player Ibrahim Shika Passes away after Long Battle with Cancer Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt News Prime Minister Moustafa Madbouly Inaugurates Two Indian Companies Business Fear & Greed Index Plummets to Lowest Level Ever Recorded amid Global Trade War Arts & Culture Zahi Hawass: Claims of Columns Beneath the Pyramid of Khafre Are Lies News Flights suspended at Port Sudan Airport after Drone Attacks News Shell Unveils Cost-Cutting, LNG Growth Plan Videos & Features Video: Trending Lifestyle TikToker Valeria Márquez Shot Dead during Live Stream Technology 50-Year Soviet Spacecraft 'Kosmos 482' Crashes into Indian Ocean
Globe and Mail
16-05-2025
- Business
- Globe and Mail
Public market insider buying at Prospera Energy (PEI)
Vittorio Valsecchi, a 10% Holder, acquired 2,550,000 Common Shares on a direct ownership basis at a price of $0.030 on May 14th, 2025. The insider also acquired 1,570,500 Common Shares on an indirect ownership basis for registered holder Valsecchi Immobilien AG at a price of $0.033 on May 15th, 2025. This represents a $128,522 investment into the company's shares and an account share holdings change of 7.9%. Let the insiders guide you to opportunity at
Medscape
14-05-2025
- Business
- Medscape
Cancer Drug PRs May Mislead Clinicians and Patients
In oncology, positive outcomes from industry-sponsored clinical trials on solid tumors are frequently first announced via press releases (PRs) — often with limited detail — well in advance of peer-reviewed publication or regulatory approval. This observation is part of a broader analysis conducted by an Italian research team led by Francesco Perrone, MD, PhD, current president of the Italian Association of Medical Oncology, and Massimo Di Maio, MD, PhD, the association's president-elect. The study was published in Journal of Cancer Policy . 'Data communication often occurs through a PR to inform quickly and effectively a large number of readers through mass communication channels,' the authors wrote in the introduction. Anna Amela Valsecchi, MD, study's lead author and a researcher at the Department of Oncology, University of Turin in Turin, Italy, told Univadis Italy, a Medscape Network platform, that the team aimed to provide an updated, comprehensive snapshot of how these PRs are structured — specifically how often they report numerical data and how quickly they are followed by peer-reviewed publications or regulatory decisions. Emphasis Over Evidence The researchers analyzed 157 PRs related to clinical trials on solid tumors published between 2018 and 2022 by the top 20 pharmaceutical companies active in oncology. They found that 75.5% of the PRs claimed achievement of the trial's primary endpoint. However, only 13% included specific quantitative results; most used vague or generalized language. Despite the lack of detail, 86% of the releases asserted the clinical relevance of the findings. Yet, the median time from PR to conference presentation was 3.1 months, and to peer-reviewed publication, 8 months. Regulatory approvals followed even later: A median of 10 months after the PR for the US Food and Drug Administration, and 15.9 months for the European Medicines Agency. Minimal Market Impact The study also examined the market response to these PRs and found that their impact on stock performance was minimal or negligible. Valsecchi noted that this market caution could reflect the absence of concrete data or the understanding that information in PRs is often preliminary and not conclusive. This portion of the analysis was conducted in collaboration with researchers from the Center for Research on Health and Social Care Management at Bocconi University in Milan, Italy. Risks of Partial Communication The findings of the Italian analysis highlight an important concern: The structure and content of pharmaceutical PRs can have meaningful effects on a broad audience, including physicians, patients, and caregivers. 'The absence of complete and detailed data makes it difficult for physicians to properly assess the clinical relevance and statistical significance of the reported outcomes,' said Valsecchi. 'For patients, this can foster unrealistic expectations, and in some cases, lead to mistrust in the doctor-patient relationship when the information in the PR does not align with the physician's clinical judgment or prescribed course of action.' Valsecchi acknowledged the challenge of communicating complex medical findings to an audience that includes both healthcare professionals and the general public. She also emphasized a broader issue: The lack of standardized guidelines for structuring PRs. This allows companies to highlight preliminary or incomplete results in ways that may unduly influence both the scientific community and patients. 'Guidelines developed by a multidisciplinary working group could help ensure that PRs prioritize scientific rigor and patient protection, rather than being overly promotional,' she concluded.
